Skip to Content

Mafenide topical Pregnancy and Breastfeeding Warnings

Mafenide topical is also known as: Sulfamylon

Medically reviewed on Sep 17, 2018

Mafenide topical Pregnancy Warnings

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

US FDA pregnancy category: C

Comments:
-The cream is not recommended in women of childbearing potential unless the burned area covers more than 20% of the total body surface area or when benefits of treatment outweigh possible risk to fetus.

See references

Mafenide topical Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Sulfamylon cream (mafenide topical)." Dow Hickam Pharmaceuticals Inc, Sugar Land, TX.
  2. "Product Information. Sulfamylon (mafenide topical)." Bertek Pharmaceuticals Inc, Sugar Land, TX.

References for breastfeeding information

  1. "Product Information. Sulfamylon cream (mafenide topical)." Dow Hickam Pharmaceuticals Inc, Sugar Land, TX.
  2. "Product Information. Sulfamylon (mafenide topical)." Bertek Pharmaceuticals Inc, Sugar Land, TX.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide